3 results
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
The primary objective of this study is to compare the overall survival (OS) associated with rAd-IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM…
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…